Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of IPM514 in Patients with Esophageal Squamous Cell Carcinoma

Inclusion criteria

• Able to provide written informed consent and can understand and agree to comply with the requirements of the study and the schedule of assessments.
• Male or female, aged ≥ 18 years.
• Histologically confirmed diagnosis of esophageal squamous cell carcinoma.
• Dose escalation and dose expansion stages: After at least one line of systemic treatment (PD-1 antibody combined with platinum-based chemotherapy) has progressed or is intolerable. The following situations are regarded as the failure of the first-line standard treatment:

• Tumor recurrence/progression during neoadjuvant/adjuvant immunotherapy combined with platinum-containing chemotherapy.
• Patients with disease recurrence within 6 months after completing neoadjuvant/adjuvant treatment, and this neoadjuvant/adjuvant treatment is also defined as first-line treatment.
• Dose escalation and dose expansion stages :At least one measurable lesion by RECIST v1.1, that is, the long diameter of non-lymph node lesions shown by CT or MRI is ≥10 mm or the short diameter of lymph node lesions is ≥15 mm. If the CT scan slice thickness is >5 mm, the minimum diameter of the lesion is twice the slice thickness (acceptable examination results within 28 days before signing the ICF).
• Neoadjuvant treatment cohort: Have not received any anti-tumor treatment for esophageal cancer, including radiotherapy, chemotherapy, surgery, etc.; and plan to receive surgical treatment after the completion of neoadjuvant treatment.
• Eastern Cooperative Oncology Group (ECOG) performance status score: 0 or 1.
• The expected survival period is ≥12 weeks.
• The HLA typing is HLA*A: 0201 and/or HLA*A: 1101.
• The organ function level in the screening period must meet the following requirements (no blood transfusion or blood products, no use of hematopoietic stimulating factors and other drugs to correct the number of blood cells before the examination):

• Absolute neutrophil count (ANC) ≥ 1.5 × 109/L;
• Platelet count (PLT) ≥ 100 × 109/L;
• Hemoglobin (Hb) ≥ 90 g/L;
• Total bilirubin (TBIL) ≤ 1.5 × ULN;
• Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 × ULN, ≤ 5 × ULN for those with liver metastasis;
• Serum creatinine (Cr) ≤ 1.5 × ULN, or creatinine clearance rate (Cockcroft-Gault formula) ≥ 45 mL/min;
• International normalized ratio (INR), prothrombin time (PT) ≤ 1.5 × ULN;
• QTc interval calculated according to the Fridericia standard, ≤ 450 ms for men and ≤ 470 ms for women;
• Urine routine/24-hour urine protein quantification: Urine protein qualitative ≤ 1+ (if urine protein qualitative ≥ 2+, then 24-hour urine protein < 1 g can be enrolled);
• Cardiac function: Left ventricular ejection fraction ≥ 50%.
• Eligible patients (male or female) with fertility must agree to adopt a medically approved physical contraceptive measure (such as an intrauterine device, condom, tubal or vas deferens ligation, etc.) during the trial and within 6 months after the last administration; Serum or urine HCG tests of women of childbearing age must be negative in the screening period.

Exclusion criteria

• After stent implantation in esophagus; Patients who are at high risk of bleeding or perforation due to significant tumor invasion of adjacent organs (aorta or trachea).
• Uncontrollable pleural effusion, pericardial effusion, or ascites requiring frequent drainage.
• Known allergy to the components of the study drug.
• Prior treatment with an mRNA vaccine.
• Subjects received major surgery within 4 weeks before the first administration or are expected to receive major surgery during the study (as judged by the investigator).
• Dose escalation and dose expansion stages: Subjects received any anti-tumor therapy, such as chemotherapy, radiotherapy, targeted therapy, immunotherapy, and biological therapy, or any investigational therapy within 28 days or 5 half-lives (whichever is shorter but at least 14 days) of the first study drug administration:
• Expected to use immunosuppressant drugs during the 4-week period before the first administration and during the study, except for corticosteroid nasal sprays, inhalants or systemic prednisone ≤ 10 mg/day and equivalent drugs of the same kind.
• With a history of organ transplantation, bone marrow transplantation or hematopoietic stem cell transplantation.
• Received live attenuated vaccines within 28 days before the first administration.
• Dose escalation and dose expansion stages: Subjects with symptomatic, untreated or requiring continuous treatment (including corticosteroids and antiepileptic drugs) of central nervous system (CNS) metastasis (for those who have received treatment in the past, those who have been clinically stable for at least 4 weeks before enrollment, have excluded evidence of new or expanded metastasis and have discontinued steroid treatment can be enrolled; those with asymptomatic brain metastasis and do not require treatment can be enrolled.
• 10 Dose escalation and dose expansion stages: The toxicity after previous anti-tumor treatment has not returned to the baseline or grade 0-1 as stipulated in NCI-CTCAE v5.0 (except for hair loss and pigmentation). Those with irreversible toxicities that are not expected to be aggravated by the investigational drug and can be enrolled after confirmation with the investigator.
• With a history of autoimmune diseases, such as systemic lupus erythematosus, psoriasis requiring systemic treatment, rheumatoid arthritis, inflammatory bowel diseases, etc. Type 1 diabetes mellitus, hypothyroidism that can only be controlled by replacement therapy, and skin diseases (such as vitiligo, psoriasis) that do not require systemic treatment can be enrolled.
• With a history of immediate allergic reaction, eczema that cannot be controlled by topical corticosteroids or asthma.
• With concomitant diseases that cannot be controlled, including but not limited to: unexplained fever > 38.5°C (subjects with tumor fever are judged by the investigator whether to include in the study), symptomatic congestive heart failure with New York Heart Association (NYHA) cardiac function classification ≥ grade 2, left ventricular ejection fraction (LVEF) < 50%, poorly controlled hypertension (systolic blood pressure > 160 mmHg and/or diastolic blood pressure > 100 mmHg after treatment, and the investigator assesses that it is of clinical significance), unstable angina pectoris or acute myocardial infarction occurred within 3 months before the first administration, poorly controlled arrhythmia; patients with chronic obstructive pulmonary disease, asthma, interstitial lung disease and those with decreased pulmonary function.
• With active infection and currently require systemic anti-infective treatment; those with active tuberculosis.
• Known history of HIV, active Treponema pallidum infection; HBsAg positive and HBV-DNA > 500 IU/L; HCV-RNA positive.
• Other situations judged by the investigator not suitable for participating in this study, including but not limited to having any diseases or histories that may confuse the study results or interfere with the patient's compliance.